|
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
|
Dec 2013
|
Curr Opin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry
|
Jul 2020
|
European Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
|
Sep 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry
|
Jul 2020
|
Annals of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry
|
May 2020
|
Annals of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Baseline characteristics and disease burden in patients in the international paroxysmal nocturnal hemoglobinuria registry
|
Jan 2014
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
|
Feb 2021
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol
|
Aug 2016
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Azacitidine in the management of patients with myelodysplastic syndromes.
|
Dec 2012
|
Ther Adv Hematol
|
myelodysplastic syndromes (MDS)
|
|
Autoimmunity and Inflammation in Myelodysplastic Syndromes
|
Jun 2016
|
Acta Haematol
|
myelodysplastic syndromes (MDS)
|
